Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

2013 trends

- PMLiVE

Trial backs role for Lynparza in second-line prostate cancer

Demonstrates potential significant benefit in treatment of disease

- PMLiVE

Basilea moves closer to US filing of novel antibiotic

Analysts expect US launch in 2022

- PMLiVE

2e Creative joins Fishawack Group

Strengthens global healthcare communications network

- PMLiVE

Senior leadership moves announced at Publicis Health

New roles will support European operations

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Edging Evolution

You don’t have to wait for your business to evolve

- PMLiVE

Eli Lilly scores positive phase 3 results for Emgality in treatment resistant migraine

Hopes to catch up with rivals in the market

- PMLiVE

AbbVie files blockbuster hopeful elagolix for uterine fibroids

Will face competition from Myovant rival

Power to the People: Why consultation is key for improved patient outcomes

Meningitis Research Foundation has been working with Say Communications to help boost our public consultation on a Roadmap to Defeat Meningitis. But with over 100 experts providing detailed information on...

Say Communications

- PMLiVE

A new era in European Parliament: policymakers need to hear from pharma

by Nick Hoile

- PMLiVE

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer

- PMLiVE

Boris pledges a £1.8bn cash injection for the NHS

Annual budget will increase 30%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links